The month ahead: September’s upcoming events
It’s back to school for biotech, with a packed conference schedule.
Opdualag sets its sights on lung
After several disappointments Bristol at last turns its Lag3/PD-1 combo to first-line lung cancer.
Agenus looks to new deals and an ex-US path
But there are no hard facts, and a Ligand obligation clouds future licensing economics.
TIGIT blows up in a trial that always looked risky
Keyvibe-008 is halted for futility, an outcome that might have been foreseen in 2022.
